CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04044859
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:01.889805+00:00
Published At: 2026-04-07T00:00:00+00:00
Record Updated At: 2026-04-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Endometrial Cancer", "Esophageal Cancer", "Esophagogastric Junction (EGJ)", "Gastric (Stomach) Cancer", "Head and Neck Cancer", "Melanoma", "Ovarian Cancer", "Non-small Cell Lung (NSCLC)", "Urothelial Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-07"
protocolSection.identificationModule.nctId: "NCT04044859"
protocolSection.identificationModule.officialTitle: "A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.